Pterostilbene

• CAT Number: R026603
• CAS Number: 537-42-8
• Molecular Formula: C16H16O3
• Molecular Weight: 256.301
• Purity: ≥95%
• Synonyms: (E)-2-(3,5-Dimethoxyphenyl)-1-(4-hydroxyphenyl)ethene; (E)-4-(3,5-Dimethoxystyryl)phenol; (E)-4-Hydroxy-3’,5’-dimethoxystilbene; 3,5-Dimethoxy-4’-hydroxy-trans-stilbene; Pterostilbene; trans-3,5-Dimethoxy-4’-hydroxystilbene; trans-Pterostilbene
• Target: Autophagy
• Storage: -20°C
• IUPAC Name: 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol
• InChI: InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+
• InChIKey: VLEUZFDZJKSGMX-ONEGZZNKSA-N
• SMILES: COC1=CC(=CC(=C1)C=CC2=CC=C(C=C2)O)OC

Pterostilbene (CAS 537-42-8) is a naturally-<wbr />occurring dimethyl ether analog of resveratrol that is abundant in blueberries. Like resveratrol, pterostilbene acts as a powerful antioxidant, suppresses the synthesis of prostaglandin E2 from lipopolysaccharide-<wbr />stimulated human peripheral blood mononuclear cells (IC50 = 1.0 μM for pterostilbene, 3.2 μM for resveratrol), and inhibits cell proliferation (IC50 = ~60 μM for both compounds). Pterostilbene blocks the activation of ERK1/2, p38 MAPK, and PI3K/Akt signaling pathways, reducing NF-<wbr />κB and AP-<wbr />1 transcriptional activation. Through these actions, pterostilbene evokes effects that prevent cancer, inflammation, and diabetes.

Reference

1.Kapetanovic, Izet M., et al. "Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats." Cancer chemotherapy and pharmacology 68.3 (2011): 593-601.
2.McCormack, Denise, and David McFadden. "Pterostilbene and cancer: current review." Journal of Surgical Research 173.2 (2012): e53-e61.
3.Estrela, José M., et al. "Pterostilbene: biomedical applications." Critical reviews in clinical laboratory sciences 50.3 (2013): 65-78.
4.MAJEED, MUHAMMED. "NATURAL PTEROSTILBENE."
5.Pan, Jing, et al. "Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy." Biomedicine & Pharmacotherapy 109 (2019): 1802-1808.